SEC Form 4 · accession 0001104659-17-057956
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carrie L. Bourdow
Director
Period of report
Sep 15, 2017
Accepted (ET)
Sep 19, 2017 · 9:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | Sep 15, 2017 | A | 10,100 | A | — | Sep 15, 2027 | Ordinary Shares | 10,100 | 10,100 | D |
Explanation of responses
- F1The exercise price is $6.86 per share.
- F2This option was granted on September 15, 2017. Vesting began on September 15, 2017 and ends on September 15, 2018. One hundred percent (100%) of the option will vest on September 15, 2018.